Charles River Laboratories International Inc. (NYSE:CRL) shares hit a new 52-week high during trading on Monday . The stock traded as high as $89.08 and last traded at $88.29, with a volume of 113,978 shares trading hands. The stock had previously closed at $87.93.

Several research analysts have recently issued reports on CRL shares. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, July 22nd. Credit Suisse Group AG started coverage on shares of Charles River Laboratories International in a report on Monday, June 20th. They set a “neutral” rating and a $84.00 price target for the company. KeyCorp reiterated a “hold” rating and set a $77.00 price target on shares of Charles River Laboratories International in a report on Sunday, May 22nd. Barclays PLC upped their price target on shares of Charles River Laboratories International from $60.00 to $65.00 and gave the stock an “underweight” rating in a report on Friday, May 20th. Finally, Gabelli started coverage on shares of Charles River Laboratories International in a report on Tuesday, April 26th. They set a “buy” rating and a $96.00 price target for the company. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $83.90.

The firm has a market cap of $4.17 billion and a P/E ratio of 27.21. The firm has a 50 day moving average of $84.18 and a 200 day moving average of $79.38.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.90 by $0.08. During the same period last year, the business posted $0.79 earnings per share. The business earned $354.90 million during the quarter, compared to the consensus estimate of $354.92 million. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. Equities analysts forecast that Charles River Laboratories International Inc. will post $4.39 EPS for the current year.

In other Charles River Laboratories International news, Director George Massaro sold 985 shares of the firm’s stock in a transaction on Monday, May 9th. The shares were sold at an average price of $82.17, for a total value of $80,937.45. Following the completion of the transaction, the director now directly owns 13,020 shares of the company’s stock, valued at approximately $1,069,853.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard F. Wallman sold 2,720 shares of the firm’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $81.00, for a total transaction of $220,320.00. Following the completion of the transaction, the director now directly owns 15,430 shares of the company’s stock, valued at $1,249,830. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in the stock. Van Berkom & Associates Inc. increased its position in shares of Charles River Laboratories International by 5.0% in the fourth quarter. Van Berkom & Associates Inc. now owns 719,334 shares of the company’s stock valued at $57,827,000 after buying an additional 34,470 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Charles River Laboratories International by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 4,182,744 shares of the company’s stock valued at $336,251,000 after buying an additional 97,314 shares during the last quarter. Morgan Stanley increased its position in shares of Charles River Laboratories International by 23.3% in the fourth quarter. Morgan Stanley now owns 293,248 shares of the company’s stock valued at $23,573,000 after buying an additional 55,393 shares during the last quarter. Mutual of America Capital Management LLC increased its position in shares of Charles River Laboratories International by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 31,278 shares of the company’s stock valued at $2,514,000 after buying an additional 164 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its position in shares of Charles River Laboratories International by 841,636.8% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 159,930 shares of the company’s stock valued at $12,857,000 after buying an additional 159,911 shares during the last quarter.

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.